Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer

Oncologist

Volumn 16, Issue 3, 2011, Pages 319-326

  Mak, Raymond H ^a   Digumarthy, Subba R ^b,c   Muzikansky, Alona ^b   Engelman, Jeffrey A ^b,c   Shepard, Jo Anne O ^b,c   Choi, Noah C ^b,c   Sequist, Lecia V ^b,c  

^a Massachusetts General Hospital Cancer Center ^*

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epidermal growth factor receptor genes; Mutation; Non small cell lung carcinoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPAMIDOL; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARD UPTAKE VALUE; MUTATIONAL ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PULMONARY ARTERY; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; WILD TYPE; CANCER STAGING; COHORT ANALYSIS; ENZYMOLOGY; GENETICS; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; POINT MUTATION; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POINT MUTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953019746     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0300     Document Type: Article

References (28)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
2. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311.
3. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
4. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
6. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
7. Sequist LV, Engelman JA, Lynch TJ. Toward noninvasive genomic screening of lung cancer patients. J Clin Oncol 2009;27:2589-2591.
8. Glynn C, Zakowski MF, Ginsberg MS. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 2010;5:344-348.
9. Yano M, Sasaki H, Kobayashi Y et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 2006;1:413-416.
10. Vesselle H, Schmidt RA, Pugsley JM et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844.
11. Kalff V, Hicks RJ, MacManus MP et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol 2001;19:111-118.
12. Ryu JS, Choi NC, Fischman AJ et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology. Lung Cancer 2002;35:179-187.
13. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al. The impact of (18)Ffluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-324.
14. Sordella R, Bell DW, Haber DA et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305: 1163-1167.
15. Buzzai M, Bauer DE, Jones RG et al. The glucose dependence of Akttransformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005;24:4165-4173.
16. Elstrom RL, Bauer DE, Buzzai M et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892-3899.
17. Ma WW, Jacene H, Song D et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27: 2697-2704.
18. Sequist LV, Joshi VA, Jänne PA et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006; 12:4403s-4408s.
19. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
20. Paquet N, Albert A, Foidart J et al. Within-patient variability of (18)FFDG: Standardized uptake values in normal tissues. J Nucl Med 2004;45: 784-788.
21. Huang CT, Yen RF, Cheng MF et al. Correlation of F-18 fluorodeoxyglucose- positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010; 27:9-15.
22. Na II, Byun BH, Kim KM et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis. Lung Cancer 2010;67:76-80.
23. Vesselle H, Salskov A, Turcotte E et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971-978.
24. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 1993;189:847-850.
25. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000;27:643-646.
26. Digumarthy SR, Fischman AJ, Kwek BH et al. Fluorodeoxyglucose positron emission tomography pattern of pulmonary lymphangitic carcinomatosis. J Comput Assist Tomogr 2005;29:346-349.
27. Kuester LB, Fischman AJ, Fan CM et al. Lipomatous hypertrophy of the interatrial septum: Prevalence and features on fusion 18F fluorodeoxyglucose positron emission tomography/CT. Chest 2005;128:3888-3893.
28. Prakash P, Kalra MK, Sharma A et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. AJR Am J Roentgenol 2010;194: 231-236.